CLDN18.2 POSITIVE
Clinical trials for CLDN18.2 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new CLDN18.2 POSITIVE trials appear
Sign up with your email to follow new studies for CLDN18.2 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets tough stomach and pancreatic cancers
Disease control Not yet recruitingThis study is testing a new drug combination called IBI343 for people with advanced stomach or pancreatic cancer that has a specific marker called CLDN18.2. The main goals are to see if the treatment is safe and if it helps shrink tumors. It will enroll about 389 adults who have …
Matched conditions: CLDN18.2 POSITIVE
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New Three-Drug attack on stomach cancer tested in surgery patients
Disease control Not yet recruitingThis study is testing whether adding a new drug called IBI343 to a standard treatment helps people with advanced stomach or gastroesophageal cancer. The goal is to shrink the tumor before surgery and prevent it from coming back afterward. It is for patients whose tumors have a sp…
Matched conditions: CLDN18.2 POSITIVE
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC